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1. Introduction 
Autism is a severe neuropsychiatric disorder characterized by impaired communication, 
significant reduction in social interaction, and repetitive and stereotyped behaviour. It is 
highly hereditable (Hoekstra et al., 2007); however, genomic alterations associated to autism 
have been found only in less than a fifth of the total number of cases. How those alterations 
ultimately cause the autistic phenotype is still very poorly understood. Besides genomic 
abnormalities, environmental and epigenetic factors may also increase the risk of 
developing autism or autistic traits. Prenatal exposure to rubella virus, cytomegalovirus, or 
to the chemical substances thalidomide and valproate are among the non-genetic causes 
linked to autism (Persico & Bourgeron, 2006), however causal relationships are not 
established. Regardless of the origins of autism, neuropathological observations are 
consistently found in several areas of autistic brains (Bauman & Kemper, 1985; Ritvo et al., 
1986), and abnormal patterns of synaptic connectivity are thought to be at the core of the 
autistic disorder (Belmonte et al., 2004). Indeed, many of the genes associated with high risk 
for autism and those increasing susceptibility are directly, or indirectly, involved in axon 
guidance, neuronal signalling, metabolism, cell differentiation and synaptic homeostasis 
(Weiss et al., 2009; Autism genome project consortium, 2007; Tabuchi et al., 2007; Toro et al., 
2010). Therefore, along with an early diagnosis (Limon 2007), the prevention and correction 
of the abnormal connectivity, and the modulation of the synaptic function are the main 
goals of current and future treatments of the pathological characteristics of the autistic 
disorders.  
Glutamate and GABA are the main excitatory and inhibitory neurotransmitters in the 
human brain and both have important roles during early development of the nervous 
system, an ontological stage when the evidence indicates that autism begins. Therefore, it is 
important to analyse the functional status of glutamatergic and GABAergic 
neurotransmission in the autistic brain. Cumulative evidence indicates that dysfunctional 
excitatory and inhibitory synaptic activities underlie several of the characteristics of autism 
and are, consequently, important targets of pharmacological intervention. In this chapter we 
describe how glutamate and GABA receptors may participate in the aetiology of autistic 
disorders and will discuss some of the methods that we have developed to study functional 
and pharmacological properties of human membrane receptors. We include information 
demonstrating that functional studies of GABA and glutamate receptors from autistic tissue 
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are feasible and important for the development of new drugs aimed at the manipulation of 
the GABAergic or glutamatergic systems in the autistic brain.  
2. Evidence of glutamatergic dysfunction in autism  
Glutamate is the main excitatory neurotransmitter in the vertebrate brain and its effects are 
exerted mainly through metabotropic (mGlu) and ionotropic (iGlu) glutamate receptors 
localized in the cellular membranes of neurons and glia. The iGlu receptors are tetrameric 
proteins that mediate fast synaptic transmission and are grouped into three classes, according 
to their differential affinity for the agonists N-methyl-D-aspartate (NMDA), kainate (KA), and 
-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) (Dingledine et al., 1999). The 
metabotropic receptors belong to the G-protein-coupled receptor superfamily, and can be 
divided in the group I (mGluR1 and mGluR5), group II (mGluR2 and mGluR3) and group III 
(mGluR4 and mGluR6-8) according to their agonist pharmacology, primary sequence and G-
protein effector coupling (Fagni et al., 2004). The increased probability of epilepsy in the 
autistic population (Tuchman & Rapin, 2002) suggests that abnormally enhanced 
glutamatergic signalling may contribute to some of the autistic characteristics. Indeed, there is 
a slight positive correlation between plasma levels of glutamate and the severity of autism that 
supports this hypothesis (Shinohe et al., 2006). Moreover, the cerebellum of autistic patients 
had increased expression of mRNAs encoding the excitatory amino acid transporter 1 
(EAAT 1) and the AMPA 1 receptor. Increments in those proteins would elevate the 
extracellular concentration of glutamate and enhance the postsynaptic activity of 
glutamatergic synapses (Puercell et al., 2001). Genome studies have found associations 
between autism and GRM8, which encodes the metabotropic glutamate receptor 8 (mGluR8) 
(Serajee et al., 2003). This receptor is localized at or near presynaptic sites and when 
activated, it negatively modulates the release of glutamate from the presynaptic terminal 
(Cartmell & Schoepp, 2000); therefore, mGluR8 dysfunction may lead to increased neuronal 
activity. Interestingly, regional subsets of presynaptic GABAergic and glutamatergic 
terminals innervating GABAergic interneurons are highly enriched with mGluR8 receptors 
in rat hippocampus (Ferraguti et al., 2005), suggesting that, if the same pattern is present in 
the human hippocampus, abnormally expressed mGluR8 would produce aberrant 
GABAergic activity and disrupt the temporal patterns of synchronic activity generated by 
inhibitory interneurons. Another important evidence suggesting a central role of glutamate 
receptors in autism comes from animal models of Fragile X syndrome, a neurological 
disorder with high prevalence of autism that is caused by silencing of the FMR1 gene and its 
translated protein, the fragile X mental retardation protein FMRP (Dölen et al., 2010). This 
protein inhibits the synthesis of a wide range of proteins by binding to actively translating 
mRNAs. FMRP is a counterbalance to the synthesis of proteins during mGluR5-mediated 
neuronal plasticity, therefore, when FMRP is dysfunctional, excessive protein synthesis 
mediated by activation of mGluR5 leads to synaptic dysfunction in Frm1 KO mice. 
Importantly, the phenotype of Frm1 KO mice can be rescued by 50% reduction of the 
expression of mGluR5, suggesting that specific antagonists of mGluR5 will have beneficial 
effects on humans with Fragile X syndrome (Dölen et al., 2010) and encourages the search of 
pharmacological approaches to treat idiopathic autism. Genome studies have also found 
several single nucleotide polymorphisms (SNPs) of GRIK2 associated with risk of autism 
(Jamain et al., 2002; Shuang et al., 2004). GRIK2 produces the kainate receptor GluK2 
(previously known as GluR6) that participates in processes of learning and memory at 
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postsynaptic sites and at presynaptic ones, modulates the release of glutamate and GABA 
from synaptic terminals (Pinheiro & Mulle, 2006). Moreover, one of the reported SNPs 
changes a methionine to an isoleucine in position 867 (M867I) of the intracellular C-
terminus, producing a structural change of the receptor that may be related to the aetiology 
of autism. Electrophysiological experiments have shown that Xenopus oocytes expressing 
the rat version of M867I-GluK2 elicit larger ion currents than oocytes expressing the wild 
type receptor, and the increment of current correlates with an enhanced density of the 
mutated receptors on the plasma membrane of the oocytes (Strutz-Seebohm et al., 2006). 
Except for a slower rate of desensitization, no major changes in the kinetic properties of the 
human or rat version of the M867I-GluK2 could account for the observed increment in the 
ion currents (Han et al., 2010); therefore, the potential link between the M867I and the 
autistic phenotype could be related mostly to alterations in the normal trafficking of GluK2 
in and out of presynaptic and postsynaptic terminals. Interestingly, despite a 99% homology 
between rat and human GluK2, both receptors had important kinetic and potency 
differences, highlighting the importance of the validation of animal models with data 
obtained from the human brain (Halladay et al., 2009; Limon et al., 2011).  
3. Evidence of GABAergic dysfunction in autism  
GABA is the most abundant and versatile neurotransmitter in the Central Nervous System 
(CNS). GABA is excitatory in the immature brain and inhibitory in the mature one (Ben-Ari, 
2008). At early stages of neural development GABA has a paracrine action on immature 
neurons. It modulates neuronal migration, stimulating developing networks and exerting a 
wide range of trophic actions that lead to the correct establishment of neural circuits (Ben-
Ari, 2008). In the adult brain, GABA participates in the generation of synchronous rhythms 
of cortical assemblies. This allows local time-precise communication among neurons and 
coherent communication with other cerebral centres, thus creating behavioural relevant 
processes (Somogyi et al., 2005). GABA actions on the membrane potential are mediated 
mostly by ionotropic receptors. Ionotropic GABA receptors in the CNS are pentameric 
channels made up by the combination of (1-6),  (2-3), (1-3) and  subunits in a 
 arrangement, with  substituting  in some extrasynaptic receptors (Olsen & 
Sieghart, 2008). They are permeable to chloride ions and whether they depolarize or 
hyperpolarize the cell membrane potential depends on the developmentally regulated 
expression of the  Na+/K+/Cl−-cotransporter, NKCC1, and the K+/Cl−-cotransporter, KCC2. 
NKCC1 is highly expressed in immature neurons and transports chloride into the neuron 
producing a high intracellular concentration of chloride, thus making GABA depolarizing. 
In mature neurons the increased expression of KCC2 and reduction of NKCC1 lowers the 
concentration of intracellular chloride and makes GABA hyperpolarizing (Mathews, 2007). 
Due to the concerted and intertwined activity of GABAergic and glutamatergic 
neurotransmission, even small net deviances of GABAergic activity could affect the 
excitation-inhibition balance in the autistic brain. Such an imbalance would reduce the ratio 
signal to noise of the sensory and procedural information in mild cases (Casanova et al., 
2006) and, in the extreme ones, it could lead to epilepsy. Actually, the incidence of epilepsy 
in one third of people with autism (Tuchman & Rapin, 2002) and the presence of paroxystic 
activity in the electroencephalogram (EEG) of approximately 68% of autistic people (Kim et 
al., 2006) is consistent with this hypothesis. These gradual alterations of the EEG traces 
suggest that aberrant electrical activity in the autistic brain is expressed as a continuum and 
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it may be present even in cases of autism with normal EEG recordings. Although abnormal 
electrical activity could have scores of causes, genetic association studies have implicated 
genes coding for the subunits 1, 2, 4, 1 and 3 of GABAA receptors as likely 
contributors for autism (Blatt et al., 2001; Hussman, 2001; Cook et al., 1998; Ma et al., 2005; 
Vincent et al., 2006; Kakinuma & Sato, 2008). Indeed, evidence from disorders that share 
overlapping autistic characteristics like Prader-Willi/Angelman syndrome (AS) and Rett 
syndrome, supports the idea that GABA receptors are convergent nodes in autistic 
phenotypes of different genetic origins. Angelman syndrome is an imprinted disorder 
caused by a maternal deficiency of chromosome 15q11-q13 (Magenis et al., 1987; Lalande, 
1996) that includes autistic characteristics and developmental delay, seizures and 
stereotyped behaviours (Samaco et al., 2005). Because the 15q11-q13 region contains genes 
for the 3, 5 and 3 subunits of GABAA receptors, the chromosomal deficiencies in 
Angelman syndrome may produce alterations in the expression of these GABA subunits. 
Knockout mice with deletions in the GABAA 5 and 3 subunits did not show a drastic 
phenotype; but a deletion in the gene for the GABAA β3 subunit produced a neonatal 
mortality of 90-95% and the survivors displayed a phenotype resembling severe forms of AS 
(Sinkkonen et al., 2003). These alterations were associated to a decreased number of GABA 
receptors in areas like the hippocampus (Sinkkonen et al., 2003) which is commonly affected 
in autism. Rett syndrome is a pervasive disorder classified within the autism spectrum 
category. Patients diagnosed with Rett syndrome, in addition to the triad of autistic 
characteristics, also show cognitive deficits, apraxia, ataxia, seizures and respiratory 
abnormalities (Chahrour & Zoghbi, 2007). Rett syndrome is the result of mutations of 
MECP2, a gene encoding the transcriptional regulator methyl-CpG-binding protein 2 
(MeCp2) (Amir et al., 1999). Mice genetically modified to reduce the function of MeCp2 
reproduce much of the phenotype of Rett syndrome. Interestingly these mice also show 
defects in the expression of the GABAA β3 subunit (Samaco et al., 2005). Recent studies have 
shown that selective deletion of MECP2 in GABAergic neurons reproduces some of the 
characteristics of regressive autism. Initially, mice with MECP2 deficiency were 
indistinguishable from the normal mice; however, after few weeks they started to develop 
stereotyped movements, compulsive grooming, impaired motor coordination, EEG 
hyperexcitability and abnormal behavioural patterns (Chao et al., 2010). The EEG 
abnormalities were tracked down to an impaired production of intracellular GABA1 and a 
consequent reduction in the quantal GABA released (Chao et al., 2010). Interestingly, 
MeCp2 reductions in frontal cortex are frequent in autism and other mental disorders 
(Nagarajan et al., 2006). Monoallellic or skewed expression of GABRB3 and a subsequent 
decrease of GABAA β3 subunit has been found in 4 out of 8 autistic patients (Hogart et al., 
2007), indicating that origins of autism are not exclusively rooted in the genome but any 
epigenetic, or environmental factor that is able to modify the function of GABA receptors 
during the development of the nervous system is prone to cause neurodevelopmental 
disorders and, particularly in the case of GABA 3 subunits, it may lead to autistic 
phenotypes. Actually, there is strong evidence implicating GABAergic dysfunction in 
                                                 
1GABA is produced by the enzymes Gad65 and Gad67 which are respectively coded by the genes Gad1 
and Gad2. In MECP2 deficient mice the expression of Gad1 and Gad2 and the immunoreactivity to 
GABA in interneurons were importantly reduced. These reductions were associated with smaller 
miniature postsynaptic events (mIPSC) without a change in their frequency (Chao et al., 2010). 
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anxiety, a common feature of autistic disorders (Amaral & Corbett., 2003). The 
hippocampus, lateral septum, periaqueductal gray matter and amygdala, which are all 
cortico-limbic structures involved in modulating anxiety states and have neuroanatomical 
changes in autism, contain major networks of GABAergic interneurons (Millan, 2003). Many 
studies focus on GABAA receptors and anxiety (Yilmazer-Hanke, 2003), but even GABAB 
(Mombereau et al., 2004) and GABAC receptors (Flores-Gracia et al., 2010) have been 
reported to be involved in anxiety-like behaviours. 
 The wide number of factors with effects on GABA receptors and the different degrees of 
changes in GABAergic signalling may explain, at least in part, the high heterogeneity found 
in the clinical phenotypes within the autism spectrum.  However whether changes in animal 
models apply to humans and what other qualitative changes are present in the human brain 
is a matter of current research. Blatt et al. (2001) reported a reduced binding of 
benzodiazepines and muscimol in the hippocampus of autistic brains, suggesting a decrease 
in the number of GABAA receptors. Posterior studies using different concentrations of 
[H3]flunitrazepan showed that the decrement of benzodiazepine binding was due to 
reductions of binding sites with no changes in the binding affinity of the receptors (Guptill 
et al., 2007). Western blot analyses of four GABAA subunits (1-3 and 3) showed reductions 
of all subunits in parietal cortex, of 1 in frontal cortex and of 1 and 3 in cerebellum of 
post-mortem autistic brains (Fatemi et al., 2009). And recent studies showed reductions in 
the binding sites to muscimol and benzodiazepines in cingulate cortex and fusiform gyrus 
of autistic brains (Oblak et al., 2009; Oblak et al., 2011). These authors also found a reduction 
in the affinity of the binding sites to muscimol, suggesting pharmacological changes in the 
receptors due to changes in the properties of the same receptors or switching of GABAA 
subunits. Indeed, an increment in the expression of 5 has been reported in the autistic brain 
(Purcell et al., 2001), and a potential remodelling of GABA subunits may explain the several 
reports of paradoxical benzodiazepine-based sedatives on severe autistic individuals with 
mental retardation (Marrosu et al., 1987; Sandman & Barron; 1992; Aman & Langworthy, 
2000). 
Undoubtedly binding experiments are, and will continue, providing important information 
about the status of GABA receptors in the autistic brain, particularly about density and 
tissue localization. However, their resolution is limited and the absence of functional 
information on the receptors is a great drawback compared with electrophysiological 
studies, where even the ion current through an activated single channel can be detected. 
Therefore, important differences between GABAA receptors might be overlooked. Another 
concern is that the benzodiazepine binding site is not present in all GABAA receptor 
isoforms and alterations in GABA receptors containing , 4 and 6 subunits, which do not 
bind classical benzodiazepines but are highly expressed in cerebellum (Sieghart, 2006), have 
not yet been appropriately addressed. It is worth noting that because of the duplication of 
the 4p12 chromosome (Ma et al., 2005), a gain of function of the 4 subunits is expected, but 
not yet explored. Also important is the fact that normal binding does not necessarily mean 
normal activation; therefore, even though the agonists and antagonists can bind to the 
receptor, determining whether the receptors are functional or not requires a 
multidisciplinary approach, using binding, biochemical and electrophysiological 
methodologies. Because GABA and glutamate are main targets of pharmacological 
intervention, a detailed analyses of their kinetic and biophysical properties will help to 
evaluate new drugs and therapeutic treatments. 
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4. Pharmacology of human receptors beyond binding studies 
We have developed two methods that allow in-depth studies of neurotransmitter receptors 
and ion channels of the human brain. The first, now widely used, involves the heterologous 
expression of human receptors in Xenopus oocytes, which, because of their size, sturdiness, 
and availability, permit experiments that would be very difficult, or impossible, to carry out 
in the human brain. The second method is the microtransplantation of native receptors that 
allows the study of native receptors still embedded in their own lipids and with their 
associated proteins. 
4.1 Heterologous expression of human receptors 
The Xenopus oocyte system is a very convenient model for studying the electrophysiological 
properties of membrane receptors (Kusano et al. 1977). G protein-coupled receptors (GPCRs) 
that are activated through the phosphatidylinositol signal pathway, and ligand gated ion 
channels, are particularly easy to study in this system. GPCRs activated through the cAMP 
signal pathway are also possible, although they are more difficult to study and require co-
expression of some of the pathway elements (Gether et al., 2002). Heterologous expression in 
Xenopus oocytes is now a classic method to study the functional impact of mutations in 
membrane receptors, and has a long tradition on the study of neurological disorders, such as 
Alzheimer’s disease and epilepsy (Dauch et al., 1997; Green et al., 2008; Palma et al. 2002). In 
autism research, the use of Xenopus oocytes is just at the beginning. However, it has already 
helped to demonstrate the gain of function of the M867I-GluK2 mutation associated with 
autism (Strutz-Seebohm et al., 2006) and the functional impact of mutations in voltage-gated 
calcium channels that lead to autistic traits in Timothy syndrome (Splawski et al., 2004). 
Timothy syndrome is a multisystem disorder characterized by syndactyly, arrhythmias and 
low survival. A high percentage of the children that survive the first years develop autism 
(Splawski et al., 2004). Timothy syndrome is caused by a substitution of glycine by arginine at 
residue 406 (G640R) of the cardiac L-type Cav1.2 channel and it is expressed in several organs 
including the brain. The expression of wild type and the mutant versions of Cav1.2 channels in 
Xenopus oocytes showed that the mutation dramatically impairs the voltage-dependent 
inactivation of the channel and leads to larger and longer calcium currents (Splawski et al., 
2004). The gain of function of the Cav1.2 channel suggests that impairments of calcium 
signalling participate in the aetiology of autism. Such central role of calcium in autism is 
supported by the recent finding that increased levels of calcium enhance the activity of the 
mitochondrial aspartate/glutamate carrier AGC1, a protein coded by the autism susceptibility 
gene SLC25A12 (Palmieri et al., 2010).  
The evidence that single mutations of glutamate- and calcium channels can lead to autism 
indicates that abnormal network excitability and intracellular signalling are critical factors in 
the generation of autistic phenotypes; and highlights the importance of understanding the 
electrophysiological properties of the receptors and channels, even in cases where no 
mutations have been reported. The expression of mRNA or cloned human receptors in 
Xenopus oocytes is a potent tool to evaluate the functional properties of GABA-, glutamate -
and calcium-channels in the autistic brain (Limon et al., 2008). Next we describe the method 
we use to express human receptors in Xenopus oocytes.  
4.1.1 Methodological insight into heterologous expression in Xenopus oocytes 
In order to study ion channels and other membrane proteins via the expression approach, 
the gene must be available in a plasmid. Nuclear injections of plasmidic DNAs can be done, 
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provided a relative high purity sample is used. We have found that plasmidic DNA isolated 
with spin columns is good enough to express receptors. The human cytomegalovirus (CMV) 
promoter is our promoter of choice. We routinely inject 14 nL at a concentration of about 200 
ng/mL, aiming at the animal pole and injecting deep to increase the likelihood of reaching 
the nucleus. Notwithstanding, the rate of successful nuclear injection is not very high, 
ending always with some oocytes that do not express the protein and with increased oocyte 
“mortality”. We also use the T7 promoter, but the level of expression is considerably lower 
(see also Geib et al., 2001). Another factor to consider is our observation that the receptor 
induced membrane currents achieved in the oocytes successfully injected with DNA are 
lower than those achieved after injecting cRNA. Therefore, our preferred choice for 
expression of channels is the cytoplasmic injection of synthetic cRNA. If the gene of interest 
is placed after any RNA Polymerase promoter such as T7, T3, SP6, synthetic cRNA can be 
produced in large quantities and with a desirable level of purity. One can use the template 
DNA and add the Polymerase, rNTPs and a reaction of a couple of hours will yield 
microgram quantities of RNA (Krieg et al., 1984). The ready to use kits are very convenient 
and even incorporate a 5’ cap analog and have the option of adding an enzyme that will 
incorporate a Poly(A)+ tail at the 3’ end to resemble more closely a natural RNA. 
Of all the kits we have tested, the mMessage mMachine kit from Ambion is the one that has 
given us the best results. That kit uses ARCA (Anti Reverse Cap Analog) 5’ cap analog 
(Stepinski et al., 2001), which prevents incorporation in the reverse orientation and maximizes 
translation efficiency. In such a way, we obtain RNAs that have strong expressional potency 
after injecting 50 nL (at ca. 1 mg/mL) into the equator of the oocyte (Limon et al., 2007; Reyes-
Ruiz et al., 2010; Limon et al., 2010). Besides its use for the expression of recombinant proteins, 
Xenopus oocytes can also express membrane proteins after injection of mRNAs directly 
isolated from human biopsy tissue or from post-mortem brains (Gundersen et al., 1984; Palma 
et al., 2002; Limon et al., 2008). For the expression of mRNA, the quality of the starting material 
is important, specially making sure the tissue is not fixed, but snap frozen in liquid nitrogen or 
CO2. We have isolated mRNAs that were able to express functional receptors and ion channels 
from tissue that was obtained several hours post-mortem and was stored frozen for several 
years (Limon et al., 2008). For the mRNA isolation procedure, it is preferable to start with at 
least one gram of tissue. We use the TRIzol method for total RNA isolation. The Poly(A)+ RNA 
is then isolated using an Oligo (dT) resin. A chromatography column is our method of choice 
because it is more convenient for larger volumes. After overnight precipitation with NaCl, the 
mRNA is thoroughly washed with 70% ethanol and resuspended in RNase free water at a 
concentration of 1 mg/mL or higher if possible. By starting with 1 g of tissue we generally 
recover about 20 or 30 µg of mRNA, suitable for at least 10 injections of 20 oocyte batches. 
Even though this is the method that has given us the best results, very often the mRNA 
obtained fails to express large currents after injection, independently of the yield or 
A260/A280 ratio, although that mRNA is usually good enough for qPCR assays. This 
methodology extends the amount of information yielded by the mRNA, because functional 
data can be cross-correlated with data from qPCR analyses of GABA subunits and synaptic 
markers. 
4.2 Microtransplantation of human receptors 
Proteins expressed de novo in Xenopus oocytes have post-translational modifications and 
membrane lipids that are specific for the oocyte, not for the human brain. Moreover, 
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microenvironmental effects on the receptor or epigenetic modifications that may have arisen 
through complex cellular signalling are not necessarily reproduced by the expression of 
mRNA.  To overcome those problems, we have been studying native human receptors using 
the microtransplantation method which is conceptually depicted in Figure 1. To 
microtransplant native membranes from human brains, part of the brain is homogenized 
and the cell membranes are isolated by centrifugation (Miledi et al., 2004). 
 
 
Fig. 1. Methods for evaluating the electrophysiological properties of human 
neurotransmitter receptors. Diagram showing the heterologous expression of proteins in 
Xenopus oocytes (top) and the microtransplantation of native cell membranes to oocytes 
(bottom). For the microtransplantation, proteoliposomes isolated from brain tissue 
specimens, containing the original native receptors, are injected into the oocytes. Within a 
few hours after injection the proteoliposomes fuse with the oocyte’s plasma membrane and 
expose the native receptors to pharmacological and biophysical experimentation. For the 
expression of de novo the human receptors, mRNA is isolated and injected into the oocytes; 
and the newly expressed receptors can then be studied in great detail. 
Cell membranes, mostly in the form of small vesicles, are adjusted to a protein concentration 
of 1-2 mg/mL and injected into an oocyte. Within a few hours the membranes, carrying 
their original neurotransmitter receptors and ion channels, begin to fuse with the oocyte 
plasma membrane. Voltage-clamp recording is then used to study the functional 
characteristics of the transplanted receptors. Oocytes with transplanted receptors can be 
studied up to several days post-injection (Miledi et al., 2004; Limon et al., 2008). 
We have assessed whether autistic brains with long post-mortem intervals still contain 
functional neurotransmitter receptors and voltage-operated ion channels that could be 
microtransplanted into Xenopus oocytes. For that purpose, we chose the cerebellum and 
temporal cortex, because neuroanatomical and biochemical studies have shown 
abnormalities in the neuronal organization of those areas (Bauman & Kemper, 1985; Bailey 
et al., 1998; Purcell et al., 2001). Our initial studies of six autistic cerebella showed that the 
amounts of microtransplanted receptors differed from their respective controls in all cases. 
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Four of them yielded responses to GABA, kainate, and glutamate that were smaller than 
their respective paired controls. The other two cases generated larger responses. In contrast, 
when the receptors of the temporal cortex were microtransplanted, the amplitudes of the 
currents induced by kainate, glutamate, and GABA by the receptors from the autistic 
membranes were larger than their controls in two of the three autistic cases (Limon et al., 
2008). Interestingly, even though the number of patients tested is low, deviations from the 
controls were already found, supporting the hypothesis of an altered GABAergic signalling 
in the autistic brain, thus encouraging further studies.  
It will be interesting to microtransplant receptors from other areas of the brain. The 
hippocampus is important in memory and learning processes; and together with the 
amygdala and prefrontal cortex participates in the negative feedback of the hypothalamic-
pituitary-adrenal (HPA) axis which in turn controls the body’s response to stress (Morris, 
2007). The hippocampus and amygdala have clear neuroanatomical alterations in autistic 
brains (Bauman & Kemper, 2005) and there is a hypothesis that prenatal stress may affect 
the HPA axis during development and increase the risk of developing autism (O’Donnell et 
al., 2009). Accordingly we evaluated if neurotransmitter receptors from hippocampi with 
long post-mortem intervals can be transplanted to Xenopus oocytes.  
4.2.1 Microtransplantation of native receptors from the hippocampus of autistic 
brains 
For these experiments we used the anterior hippocampus from two autistic brains and two 
matching control brains (Table 1). Cell membranes were prepared as previously reported 
(Limon et al., 2008) and then injected into the equator of Xenopus oocytes. Ligand-activated 
ion currents were observed after 24 h post-injection in oocytes voltage-clamped at -80 mV, 
clearly indicating the successful transplantation of functional GABA and glutamate 
receptors (Fig. 2). Oocytes injected with cell membranes derived from both autistic brains 
showed smaller GABA-currents than their respective controls (Fig. 3); suggesting that the 
number of GABA receptors is decreased in the hippocampus of autistic brains. However, for 
the moment we have not discounted the possibility that changes in the properties of the 
receptors, or in the efficiency of membrane fusion, produce a decrease of the currents 
without a decrease of receptor density. Kainate induced currents were reduced in the 
autistic sample from the older patient and unaffected in the other autistic sample. Evidently 
further studies are needed including a statistically meaningful number of samples. 
However, it is already evident that the microtransplantation of receptors from 
hippocampus, even with long post-mortem intervals is possible.  
 
Case Dx Age (years) Gender PMI (h) 
B6076 Control 38 Male 25.47 
B6401 Autism 39 Male 13.95 
B6207 Control 16 Male 26.16 
B5666 Autism 8 Male 22.16 
Table 1. Characteristics of the tissue used. Dx, diagnosis; PMI, post-mortem interval. 
An important advantage of the microtransplantation method is that the biophysical studies are 
done directly on native receptors that were once in the human brain and are still embedded in 
their original lipids and with their own cohort of associated proteins. Another advantage is the 
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rapid and high yield of functional and pharmacological information, obtained from minimal 
amounts of protein. For comparative purposes, consider for example that to prepare a 2-
dimensional gel ranges of 2-2000 µg of protein are needed (Adams & Gallagher, 2005); for a 
Western Blot about 40 µg is recommended. Even for mass spectrometry-based proteomics few 
µg of total protein is used. In contrast, with the microtransplantation method 50 ng of protein 
are injected into a single oocyte and a full dose response plus several pharmacological 
experiments can be done with such a small amount of protein. 
 
 
Fig. 2. Sample responses to 1 mM GABA and 100 µM kainate of an oocyte injected with 
membranes from an autistic hippocampus (above; case B6076, PMI = 25.47 h) and of another 
oocyte injected with its matching control (below, case B6401, PMI = 13.95 h).  
5. Conclusion  
Strong evidence indicates that autism is a developmental synaptic disorder that affects the 
processing of behavioural relevant information. Although the causes of autism are still not 
known, GABAergic and glutamatergic synapses appear to be convergent nodes of genetic, 
epigenetic, and probably environmental factors causing the autistic phenotype. Even small 
alterations in GABAergic or glutamatergic signalling produce autistic characteristics in 
animal models, and it is highly probable that a similar phenomenon is present in the human 
brain. GABA and glutamate receptors are also important targets of pharmacological 
interventions and a detailed knowledge of their function in the human brain will improve 
the use and design of molecules with therapeutic activity. The microtransplantation of the 
original receptors from postmortem brains coupled to the expression of receptors by post-
mortem mRNAs will help to determine in great detail the type, number, and functional 
properties of autistic neurotransmitter receptors and channels. These procedures will help to 
decipher the functional impact of genetic and epigenetic factors in autism. Furthermore, the 
microtransplantation method will help to determine the mode of action of the medicines 
presently used to treat autism, and help to develop new medicines and evaluate their 
pharmacological activity.  
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Fig. 3. Responses to 1 mM GABA and 100 µM kainate in oocytes injected with membrane 
preparations from anterior hippocampus of autistic and control brains (n=5-6 oocytes/case). 
Data is mean ± SEM. 
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